Already a member?

Wider-than-Expected Loss at Anacor - Analyst Blog

Anacor Pharmaceuticals, Inc.
(
ANAC
) reported third quarter 2013 net loss per share of 41 cents,
wider than the Zacks Consensus Estimate of a loss of 36 cents but
narrower than the year-ago loss of 46 cents per share.

Third quarter revenues were $3.6 million, compared with $2.5
million in the year-ago quarter. Revenues beat the Zacks
Consensus Estimate of $3 million.

Research and development expenses fell 8.1% year over year to
$12.5 million. The decline was due to lower clinical expenses for
tavaborole.

Selling, general and administrative expenses increased 147.5%
year over year to $6.8 million, primarily driven by higher legal
fees related to disputes with
Valeant PharmaceuticalsInternational, Inc.
(
VRX
) and marketing activities for tavaborole.

Pipeline Update

Anacor's pipeline includes several topical candidates
including an anti-fungal onychomycosis candidate, tavaborole. In
Jul 2013, Anacor submitted a New Drug Application (NDA) for
tavaborole to the U.S. Food and Drug Administration (FDA) for the
prevention of onychomycosis. The FDA accepted Anacor's NDA in Oct
2013. With the FDA accepting the NDA, a response regarding
tavaborole should be out by Jul 29, 2014. Anacor intends to
launch tavaborole in the second half of 2014 assuming FDA
approval.

In Jul 2013, Anacor commenced the MUSE (maximal use systemic
exposure) study in children to evaluate the effects of its atopic
dermatitis candidate, AN2728. Anacor started a TQT (thorough QT)
study on the candidate in Aug 2013. Results from both studies are
expected by year end. For AN2728, a phase III study in atopic
dermatitis will start in the first half of 2014, depending on the
completion of the MUSE and TQT studies.

Other Information

In Oct 2013, Anacor inked a deal with the United States
Department of Defense, Defense Threat Reduction Agency (DTRA) to
design and discover new classes of systemic antibiotics for a
time period of three and a half years.

Anacor reached an agreement with Valeant relating to the
breach of contract disputes with Dow Pharmaceutical
Sciences, Inc. and Medicis Pharmaceutical Corporation in Oct
2013. Valeant paid $142.5 million to settle both the disputes
with Anacor on Nov 7, 2013. Valeant acquired Dow Pharma in Dec
2008 and Medicis in Dec 2012.

Financial Outlook

The company expects to end the year with cash, cash
equivalents and short-term investments of at least $160 million.
This includes the arbitration proceeds from Valeant.

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page;
unless you change your configuration again, or you delete your
cookies. Are you sure you want to change your settings?